07:42 AM EDT, 05/06/2024 (MT Newswires) -- Xeris Biopharma Holdings ( XERS ) said Monday it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics for the development and commercialization of a glucagon product.

Under the agreement, Beta Bionics will utilize Xeris' XeriSol technology on its bi-hormonal pump and pump systems for people with diabetes.

Xeris may potentially receive development payments and low double-digit royalties based on future sales of the Xeris glucagon for pumps and pump systems, the company said.

Price: 1.9900, Change: +0.10, Percent Change: +5.29